Supplementary Information

**Fabrication of hyaluronic acid-targeted supramolecular delivery platform with multi-mode drug release**

Kaixuan Jianga, Yuxi Gea, Wenhui Wua, Meiran Xiea, Hu He\*b, Ruyi Sun\*a

a East China Normal University, School of Chemistry and Molecular Engineering, Shanghai 200241, People’s Republic of China

b Hangzhou SynRx Therapeutics Biomedical Technology Co., Hangzhou, Zhejiang, China

Corresponding author email addresses: E-mail: rysun@chem.ecnu.edu.cn (Ruyi Sun)

Corresponding author email addresses: E-mail: hehu@synrx.cn (Hu He)



**Figure S1.** The synthetic routes of HSEFc-S-S-p(AAm-co-AN) and HACD.




**Figure S2.** CV curves of FcA- and β-CD/FcA- with different mole ratios. The analysis (25 °C, 100 mV s-1) was performed with an HSEFc-S-S-p(AAm-co-AN) concentration of 100 mM in Na2HPO4 solution (200 mM, pH 9.2).



**Figure S3.** CV curves of HSEFc-S-S-p(AAm-co-AN) and HACD/HSEFc-S-S-p(AAm-co-AN)NPs. The analysis (25 °C, 100 mV s-1) was performed with an HSEFc-S-S-p(AAm-co-AN) concentration of 100 mM in Na2HPO4 solution (200 mM, pH 9.2).



**Figure S4.** TEM images of the HA/HSEFc-S-S-p(AAm-co-AN) (scale bar: 200 nm).



**Figure S5.** TEM images of the HACD/HSEFc-S-S-p(AAm-co-AN)NPs (scale bar: 200 nm).



**Figure S6.** Variation in HeLa cells viability as a function of the concentration of DOX/HACD/HSEFc-S-S-p(AAm-co-AN)NPs.



**Figure S7.** Variation in HeLa cells viability as a function of the concentration of DOX.